Monitoring and Evaluation of Patient Engagement in Health Product Research and Development: Co-Creating a Framework for Community Advisory Boards

Journal of Patient-Centered Research and Reviews

Richard H. Pitt¹  Hilde De Keyser²  Denise Dunne³  Rob Camp⁴  François Houÿez⁴  Elena Zhuravleva⁵  Laura McKeaveney⁶  Meagan F. Vaughn⁷  Davide Marchi⁸  Lidewij Eva Vat⁹  Carina A.C.M. Pittens⁹  Sevgi E. Fruytier⁹  Tjerk Jan Schuitmaker-Warnaar⁹ 

[1]Boehringer Ingelheim International GmbH, Ingelheim, Germany

[2]CF Europe, Brussels, Belgium

[3]Cystinosis Ireland, Dublin, Ireland

[4]European Organisation for Rare Diseases (EURORDIS), Barcelona, Spain

[5]F. Hoffmann–La Roche Ltd, Basel, Switzerland

[6]Novartis AG, Basel, Switzerland

[7]Translate Bio, Inc., Lexington, MA

[8]Vertex Pharmaceuticals (Europe) Limited, London, United Kingdom

[9]Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

关键词: patient engagement;    patient participation;    rare diseases;    program evaluation;    drug development;   

DOI  :  10.17294/2330-0698.1859

来源: DOAJ

【 授权许可】

Unknown